Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + sintilimab + electroacupuncture in MSS metastatic colorectal cancer
ChiCTR2400085473Phase 2Recruiting
- Sponsor
- The First People’s Hospital of Changzhou
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and sintilimab in colorectal adenocarcinoma, sponsored by The First People’s Hospital of Changzhou. Primary endpoint: Overall survival. Started Apr 2024; status: recruiting.
02
Drugs
regorafenibsintilimab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400085473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085473.